S

Stille AB
STO:STIL

Watchlist Manager
Stille AB
STO:STIL
Watchlist
Price: 203 SEK -1.93% Market Closed
Market Cap: 1.8B SEK
Have any thoughts about
Stille AB?
Write Note

Stille AB
Capital Expenditures

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Stille AB
Capital Expenditures Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Capital Expenditures CAGR 3Y CAGR 5Y CAGR 10Y
S
Stille AB
STO:STIL
Capital Expenditures
-kr12.6m
CAGR 3-Years
18%
CAGR 5-Years
-20%
CAGR 10-Years
-19%
Elekta AB (publ)
STO:EKTA B
Capital Expenditures
-kr1.6B
CAGR 3-Years
-25%
CAGR 5-Years
-20%
CAGR 10-Years
N/A
S
Surgical Science Sweden AB
STO:SUS
Capital Expenditures
-kr47.2m
CAGR 3-Years
-67%
CAGR 5-Years
-44%
CAGR 10-Years
N/A
CellaVision AB
STO:CEVI
Capital Expenditures
-kr76.4m
CAGR 3-Years
-19%
CAGR 5-Years
-31%
CAGR 10-Years
-17%
Getinge AB
STO:GETI B
Capital Expenditures
-kr1.4B
CAGR 3-Years
-9%
CAGR 5-Years
0%
CAGR 10-Years
N/A
Arjo AB (publ)
STO:ARJO B
Capital Expenditures
-kr403m
CAGR 3-Years
21%
CAGR 5-Years
9%
CAGR 10-Years
N/A
No Stocks Found

Stille AB
Glance View

Market Cap
1.8B SEK
Industry
Health Care

Stille AB engages in the development and sale of medical equipment. The company is headquartered in Torshaella, Sodermanlands. The product portfolio is divided into two business lines. The Surgery business area develops, produces and markets handcrafted, forged surgical instruments for all fields of open surgery, with an emphasis on cardiovascular surgery, and reconstructive and aesthetic plastic surgery. Its products include scissors, forceps, artery forceps, needle holders and clamps, among others. The Patient Positioning area develops and manufactures two main groups of procedure-specific specialized tables for cardiovascular surgery and gynecology, urology and urodynamic examinations. As of December 31, 2011, the Company had two wholly owned subsidiaries, Stille Surgical Inc. and Stille Incentive AB. As of December 30, 2011, the it's largest shareholder was Linc Invest AB (39.81%). On September 2, 2013, the Company sold its business unit, Sonesta, to ADDvise Lab Solutions publ AB.

STIL Intrinsic Value
286.89 SEK
Undervaluation 29%
Intrinsic Value
Price
S

See Also

What is Stille AB's Capital Expenditures?
Capital Expenditures
-12.6m SEK

Based on the financial report for Sep 30, 2024, Stille AB's Capital Expenditures amounts to -12.6m SEK.

What is Stille AB's Capital Expenditures growth rate?
Capital Expenditures CAGR 10Y
-19%

Over the last year, the Capital Expenditures growth was -9%. The average annual Capital Expenditures growth rates for Stille AB have been 18% over the past three years , -20% over the past five years , and -19% over the past ten years .

Back to Top